The recommendation follows updated results from the DESTINY-Breast03 phase 3 trial, announced by the companies earlier this month, in which Enhertu demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to standard of care trastuzumab emtansine in patients previously treated with trastuzumab and a taxane.
The observed survival benefit was consistent across analysed subgroups, including patients with or without baseline brain metastases, with or without baseline visceral disease, those who were HR-positive or HR-negative, and regardless of prior pertuzumab or lines of systemic therapy…
